{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-021080","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.105007+00:00","generated_at":"2026-06-24T04:25:41.314595+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lyell Immunopharma reports Q2 2022 net loss of $36.3M; cash of $787M funds into 2025","bullets":["Revenue of $35.7M (vs $2.6M YoY), driven by $35.3M from concluding GSK hematological cancer research.","Net loss GAAP $36.3M (vs $62.6M YoY); non-GAAP net loss $10.3M (vs $38.1M YoY).","R&D expense $43.7M (vs $46.4M YoY); G&A expense $30.5M (vs $19.1M YoY) due to stock compensation.","Cash, equivalents and marketable securities of $787.0M as of June 30, 2022, providing funding into 2025.","Lead CAR T candidate LYL797 on track for initial clinical data in 2023; preclinical data presented at ASGCT."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-021080","json":"https://secwatch.observer/filing/0001628280-22-021080.json","markdown":"https://secwatch.observer/filing/0001628280-22-021080.md","text":"https://secwatch.observer/filing/0001628280-22-021080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000162828022021080/0001628280-22-021080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000162828022021080/lyel-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:25:41.314595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}